Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption
Objectives: Pancreatic enzyme replacement therapy (PERT) remains a backbone in the nutritional treatment of cystic fibrosis. Currently, there is a lack of an evidence-based tool that allows dose adjustment. To date, no studies have found an association between PERT dose and fat absorption. Therefore...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Aran Ediciones
|
Series: | Revista Espanola de Enfermedades Digestivas |
Subjects: | |
Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017001000003&lng=en&tlng=en |
id |
doaj-4457fe6e8ca04c328b5984c7c9e8e902 |
---|---|
record_format |
Article |
spelling |
doaj-4457fe6e8ca04c328b5984c7c9e8e9022020-11-24T21:11:43ZengAran EdicionesRevista Espanola de Enfermedades Digestivas1130-01081091068468910.17235/reed.2017.4951/2017S1130-01082017001000003Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorptionJoaquim Calvo-Lerma0Sandra Martínez-Barona1Etna Masip2Victoria Fornés3Carmen Ribes-Koninckx4La Fe Health Research InstituteLa Fe Health Research InstituteLa Fe Health Research InstituteLa Fe Health Research InstituteLa Fe Health Research InstituteObjectives: Pancreatic enzyme replacement therapy (PERT) remains a backbone in the nutritional treatment of cystic fibrosis. Currently, there is a lack of an evidence-based tool that allows dose adjustment. To date, no studies have found an association between PERT dose and fat absorption. Therefore, the aim of the study was to assess the influence of both the PERT dose and the variability in this dose on the coefficient of fat absorption (CFA). Methods: This is a retrospective longitudinal study of 16 pediatric patients (192 food records) with three consecutive visits to the hospital over a twelve-month period. Dietary fat intake and PERT were assessed via a four-day food record and fat content in stools was determined by means of a three-day stool sample collection. A beta regression model was built to explain the association between the CFA and the interaction between the PERT dose (lipase units [LU]/g dietary fat) and the variability in the PERT dose (standard deviation [SD]). Results: The coefficient of fat absorption increased with the PERT dose when the variability in the dose was low. In contrast, even at the highest PERT dose values, the CFA decreased when the variability was high. The confidence interval suggested an association, although the analysis was not statistically significant. Conclusion: The variability in the PERT dose adjustment should be taken into consideration when performing studies on PERT efficiency. A clinical goal should be the maintenance of a constant PERT dose rather than trying to obtain an optimal value.http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017001000003&lng=en&tlng=enCystic fibrosisEnzyme to substrate ratioPancreatic enzyme replacement therapy (PERT)Enzymatic supplementsCoefficient of fat absorption. Variability |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joaquim Calvo-Lerma Sandra Martínez-Barona Etna Masip Victoria Fornés Carmen Ribes-Koninckx |
spellingShingle |
Joaquim Calvo-Lerma Sandra Martínez-Barona Etna Masip Victoria Fornés Carmen Ribes-Koninckx Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption Revista Espanola de Enfermedades Digestivas Cystic fibrosis Enzyme to substrate ratio Pancreatic enzyme replacement therapy (PERT) Enzymatic supplements Coefficient of fat absorption. Variability |
author_facet |
Joaquim Calvo-Lerma Sandra Martínez-Barona Etna Masip Victoria Fornés Carmen Ribes-Koninckx |
author_sort |
Joaquim Calvo-Lerma |
title |
Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption |
title_short |
Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption |
title_full |
Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption |
title_fullStr |
Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption |
title_full_unstemmed |
Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption |
title_sort |
pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption |
publisher |
Aran Ediciones |
series |
Revista Espanola de Enfermedades Digestivas |
issn |
1130-0108 |
description |
Objectives: Pancreatic enzyme replacement therapy (PERT) remains a backbone in the nutritional treatment of cystic fibrosis. Currently, there is a lack of an evidence-based tool that allows dose adjustment. To date, no studies have found an association between PERT dose and fat absorption. Therefore, the aim of the study was to assess the influence of both the PERT dose and the variability in this dose on the coefficient of fat absorption (CFA). Methods: This is a retrospective longitudinal study of 16 pediatric patients (192 food records) with three consecutive visits to the hospital over a twelve-month period. Dietary fat intake and PERT were assessed via a four-day food record and fat content in stools was determined by means of a three-day stool sample collection. A beta regression model was built to explain the association between the CFA and the interaction between the PERT dose (lipase units [LU]/g dietary fat) and the variability in the PERT dose (standard deviation [SD]). Results: The coefficient of fat absorption increased with the PERT dose when the variability in the dose was low. In contrast, even at the highest PERT dose values, the CFA decreased when the variability was high. The confidence interval suggested an association, although the analysis was not statistically significant. Conclusion: The variability in the PERT dose adjustment should be taken into consideration when performing studies on PERT efficiency. A clinical goal should be the maintenance of a constant PERT dose rather than trying to obtain an optimal value. |
topic |
Cystic fibrosis Enzyme to substrate ratio Pancreatic enzyme replacement therapy (PERT) Enzymatic supplements Coefficient of fat absorption. Variability |
url |
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017001000003&lng=en&tlng=en |
work_keys_str_mv |
AT joaquimcalvolerma pancreaticenzymereplacementtherapyincysticfibrosisdosevariabilityandcoefficientoffatabsorption AT sandramartinezbarona pancreaticenzymereplacementtherapyincysticfibrosisdosevariabilityandcoefficientoffatabsorption AT etnamasip pancreaticenzymereplacementtherapyincysticfibrosisdosevariabilityandcoefficientoffatabsorption AT victoriafornes pancreaticenzymereplacementtherapyincysticfibrosisdosevariabilityandcoefficientoffatabsorption AT carmenribeskoninckx pancreaticenzymereplacementtherapyincysticfibrosisdosevariabilityandcoefficientoffatabsorption |
_version_ |
1716752942658224128 |